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Abstract
Background: Genome-wide association studies identified PTPN2 (protein tyrosine phosphatase, non-receptor type 2) as
susceptibility gene for inflammatory bowel diseases (IBD). However, the exact role of PTPN2 in Crohn’s disease (CD) and
ulcerative colitis (UC) and its phenotypic effect are unclear. We therefore performed a detailed genotype-phenotype and
epistasis analysis of PTPN2 gene variants.
Methodology/Principal Findings: Genomic DNA from 2131 individuals of Caucasian origin (905 patients with CD, 318
patients with UC, and 908 healthy, unrelated controls) was analyzed for two SNPs in the PTPN2 region (rs2542151,
rs7234029) for which associations with IBD were found in previous studies in other cohorts. Our analysis revealed a
significant association of PTPN2 SNP rs2542151 with both susceptibility to CD (p=1.95610
25; OR 1.49 [1.34–1.79]) and UC
(p=3.87610
22, OR 1.31 [1.02–1.68]). Moreover, PTPN2 SNP rs7234029 demonstrated a significant association with
susceptibility to CD (p=1.30610
23; OR 1.35 [1.13–1.62]) and a trend towards association with UC (p=7.53610
22; OR 1.26
[0.98–1.62]). Genotype-phenotype analysis revealed an association of PTPN2 SNP rs7234029 with a stricturing disease
phenotype (B2) in CD patients (p=6.62610
23). Epistasis analysis showed weak epistasis between the ATG16L1 SNP
rs2241879 and PTPN2 SNP rs2542151 (p=0.024) in CD and between ATG16L1 SNP rs4663396 and PTPN2 SNP rs7234029
(p=4.68610
23) in UC. There was no evidence of epistasis between PTPN2 and NOD2 and PTPN2 and IL23R. In silico analysis
revealed that the SNP rs7234029 modulates potentially the binding sites of several transcription factors involved in
inflammation including GATA-3, NF-kB, C/EBP, and E4BP4.
Conclusions/Significance: Our data confirm the association of PTPN2 variants with susceptibility to both CD and UC,
suggesting a common disease pathomechanism for these diseases. Given recent evidence that PTPN2 regulates
autophagosome formation in intestinal epithelial cells, the potential link between PTPN2 and ATG16L1 should be further
investigated.
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Introduction
Inflammatory bowel diseases (IBD), encompassing Crohn’s
disease (CD) and ulcerative colitis (UC), are characterized by
chronic intestinal inflammation caused by a dysregulated interac-
tion with bacterial antigens, resulting in an exaggerated immune
response in a genetically predisposed host [1,2]. Genome-wide
association studies (GWAS) have substantially improved our
understanding of the molecular pathways leading to CD or UC
and have so far identified almost 100 distinct genetic loci that confer
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33682IBD susceptibility including novel pathways involved in autophagy,
innate immune response and proinflammatory IL-23/Th17 cell
activation [3,4,5,6,7,8,9]. However, for many of the gene regions
identified by GWAS, there is still lack of functional data and limited
knowledge how these gene variants modify the IBD phenotype.
One of the recent candidate genes identified by GWAS is
protein tyrosine phosphatase non-receptor type 2 (PTPN2),
encoding the enzyme tyrosine-protein phosphatase non-receptor
type 2, a member of the protein tyrosine kinases (PTP)
superfamily. So far, two isoforms of PTPN2 generated from
alternative splicing have been identified: a major TC45 isoform
(45 kDa) containing a nuclear localization sequence and a less
abundant TC48 isoform (48 kDa) anchored to the endoplasmic
reticulum [10]. For TC45, various targets including Janus kinases
(JAKs), signal transducer and activator of transcription (STAT) 1
and 3, p42/44 mitogen-activated protein kinase (MAPK) (extra-
cellular signal–related kinase [ERK]), epidermal growth factor
receptor (EGFR) as well as insulin receptor b (IRb) [11,12,13,14]
have been identified. So far, PTPN2 has been shown to be a
susceptibility gene for celiac disease and for diabetes modifying
beta-cell responses to viral RNA and apoptosis [15,16,17]. Recent
GWAS identified PTPN2 as susceptibility gene for CD
[18,19,20,21], while a GWAS meta-analyses in UC patients
showed also an association with UC [22]. Interestingly, an analysis
in a Dutch-Belgian cohort [23] revealed that the PTPN2 SNP
rs2542151 was only moderately CD-associated in a CD subcohort
of smokers (p=0.04), but not in the entire cohort or in the non-
smoking CD cohort, implicating additional modifying factors
requiring further functional analysis and replication studies.
Given the overall lack of detailed phenotype analyses of PTPN2
in IBD, we initiated an extensive genotype-phenotype analysis in a
large German cohort of IBD patients including 905 patients with
CD, 318 patients with UC, and 908 healthy, unrelated controls
which were genotyped for the two SNPs rs2542151 and rs7234029
in the PTPN2 region. Based on a pathway analysis of gene
relationships across implicated loci (GRAIL) of a recent GWAS
meta-analysis in CD demonstrating a potential interaction
between the PTPN2-related gene PTPN22 and NOD2 [19], we
also performed analysis for gene-gene interaction between PTPN2
and NOD2 regarding CD susceptibility. Moreover, considering
that PTPN2 gene variants are - similar to IL23R gene variants -
Table 1. Demographic characteristics of the IBD study
population.
Crohn’s
disease
Ulcerative
colitis Controls
n=905 n=318 n=908
Gender
Male (%) 48.8 52.2 62.7
Female (%) 51.2 47.8 37.3
Age (yrs)
Mean 6 SD 40.9613.3 44.2614.8 45.8610.3
Range 15–83 17–88 19–68
Body mass index
Mean 6 SD 23.064.2 23.964.5
Range 13–41 15–54
Age at diagnosis (yrs)
Mean 6 SD 26.1612.4 28.9614.5
Range 1–78 2–81
Disease duration (yrs)
Mean 6 SD 13.468.9 12.268.3
Range 0–47 1–50
Positive family history
of IBD (%)
16.7 17.4
doi:10.1371/journal.pone.0033682.t001
Table 2. Associations of PTPN2 gene markers in the CD and UC case-control cohorts.
PTPN2 SNP Minor allele Crohn’s disease Ulcerative colitis Controls
n=905 n=318 n=908
MAF p value OR [95% CI] MAF p value OR [95% CI] MAF
rs2542151 G 0.182 1.95610
25 1.49 [1.34–1.79] 0.164 3.87610
22 1.31 [1.02–1.68] 0.130
rs7234029 G 0.177 1.30610
23 1.35 [1.13–1.62] 0.167 7.53610
22 1.26 [0.98–1.62] 0.137
Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and
UC case-control cohorts.
doi:10.1371/journal.pone.0033682.t002
Table 3. Haplotype analysis for the PTPN2 SNPs rs2542151
and rs7234029 in the CD case-control cohort.
PTPN2 SNP1 PTPN2 SNP2 Haplotype OR 95% CI p-value
rs2542151 rs7234029 GG 1.42 1.04–1.93 1.46610
23
rs2542151 rs7234029 TG 1.18 0.82–1.71 2.93610
21
rs2542151 rs7234029 GA 1.45 0.92–2.32 1.88610
22
rs2542151 rs7234029 TA 0.70 0.62–0.80 2.37610
25
OR=odds ratio; 95% CI=95% confidence interval.
doi:10.1371/journal.pone.0033682.t003
Table 4. Haplotype analysis for the PTPN2 SNPs rs2542151
and rs7234029 in the UC case-control cohort.
PTPN2 SNP1 PTPN2 SNP2 Haplotype OR 95% CI p-value
rs2542151 rs7234029 GG 1.21 0.83–1.77 0.220
rs2542151 rs7234029 TG 1.34 0.77–2.33 0.147
rs2542151 rs7234029 GA 1.37 0.76–2.47 0.151
rs2542151 rs7234029 TA 0.76 0.63–0.91 0.015
OR=odds ratio; 95% CI=95% confidence interval.
doi:10.1371/journal.pone.0033682.t004
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idiopathic arthritis [24] or type 1 diabetes [17], we also analysed
for epistasis between PTPN2 and IL23R. In addition, a very recent
study suggests that PTPN2 regulates autophagosome formation in
intestinal epithelial cells [25]. We therefore analyzed also for
potential epistasis with the CD susceptibility gene ATG16L1.
Methods
Ethics statement
Before participating in the study, all patients gave written,
informed consent. In case of minors, patients’ parents gave written
consent. The Ethics committee of the Medical Faculty of Ludwig-
Maximilians-University Munich approved this study. The study
protocol was in accordance with the ethical principles for medical
research involving human subjects of the Helsinki Declaration.
Study population and genotype-phenotype analysis
Overall, 2131 individuals of Caucasian origin including 905 CD
patients, 318 UC patients, and 908 healthy, unrelated controls
were included in the study population. Patients with indeterminate
colitis were excluded from the study. For phenotype analysis, the
demographic and clinical data (behaviour and location of IBD,
disease-related complications, surgical history or immunosuppres-
sive therapy) of the patients were recorded by patient chart
analysis and a detailed questionnaire including an interview at
time of enrolment. The demographic characteristics of the IBD
study population were collected blind to the results of the genotype
Table 5. Genotype-phenotype associations of the PTPN2 SNP rs2542151 in CD patients.
PTPN2 SNP rs2542151 TT (n=611)T G ( n=258)G G ( n=36)P G ORG [95% CI]
Age at diagnosis (yr) (n=817)
Mean 6 SD 25.32611.91 28.06613.48 25.1969.61 5.96610
22 0.75
Range 1–71 2–78 15–49 [0.56–1.01]
Age at diagnosis (n=817)
,=16 years (A1) 126 (22.7%) 38 (16.1%) 4 (14.8%) 4.53610
22 0.67 [0.45–0.99]
(n=168) (A1 vs. A2)
17–40 years (A2) 368 (66.4%) 161 (68.2%) 22 (81.5%) 0.285 0.79 [0.50–1.22]
(n=551) (A2 vs. A3)
.40 years (A3) 60 (10.8%) 37 (15.7%) 1 (3.7%) 1.89610
22 0.53 [0.31–0.90]
(n=98) (A1 vs. A3)
Location (n=770)
Terminal ileum (L1) (n=113) 73 (14.3%) 33 (14.4%) 7 (21.9%) 0.715 1.08 [0.71–1.64]
Colon (L2) 62 (12.2%) 31 (13.5%) 4 (12.5%) 0.627 1.17
(n=97) [0.72–1.74]
Ileocolon (L3) 366 (71.9%) 163 (71.2%) 21 (65.6%) 0.682 0.93
(n=550) [0.67–1.30]
Upper GI (L4) 8 (1.6%) 2 (0.9%) 0 (0%) 0.360 0.48
(n=10) [0.10–2.29]
Behaviour (n=747)
Non-stricturing/Non-penetrating (B1) 111 (24.3%) 49 (23.6%) 12 (42.9%) 0.645 1.08
(n=172) [0.76–1.55]
Stricturing (B2) 123 (27.0%) 57 (27.4%) 7 (25.0%) 0.941 1.01
(n=187) [0.71–1.44]
Penetrating 222 (48.7%) 102 (49.0%) 9 (32.1%) 0.729 0.95
(B3) (n=333) [0.70–1.29]
Use of immunosuppressive agents no: 65 (16.6%) 35 (20.3%) 5 (22.7%) 0.237 0.77
(n=585) yes: 326 (83.4%) 137 (79.7%) 17 (77.3%) [0.50–1.19]
Surgery because of CD no: 265 (48.7%) 106 (44.7%) 19 (59.4%) 0.547 1.09
(n=813) yes: 279 (51.3%) 131 (55.3%) 13 (40.6%) [0.82–1.47]
Fistulas no: 290 (52.3%) 121 (50.2%) 18 (56.3%) 0.699 1.06
(n=827) yes: 264 (47.7%) 120 (49.8%) 14 (43.8%) [0.79–1.42]
Stenosis no: 234 (42.0%) 90 (37.5%) 16 (50.0%) 0.404 1.13
(n=829) yes: 323 (58.0%) 150 (62.5%) 16 (50.0%) [0.84–1.53]
PG: p-value for association comparing carriers of the G-allele to individuals homozygous for T. Association results for age at diagnosis are based on median split.
Uncorrected p-values,0.05 are depicted in bold. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis
tested: n=15, resulting in a significance threshold of p,3.33610
23).
doi:10.1371/journal.pone.0033682.t005
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according to established guidelines based on endoscopic, radio-
logical, and histopathological criteria [26]. In CD patients, the
Montreal classification based on the age at diagnosis (A), location
(L), and behaviour (B) of disease [27] was used for assessment. In
patients with UC, anatomic location was also based on the
Montreal classification using the criteria ulcerative proctitis (E1),
left-sided UC (distal UC; E2), and extensive UC (pancolitis; E3).
DNA extraction and genotyping of the PTPN2 variants
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany) according
to the manufacturer’s guidelines. The two PTPN2 SNPs rs2542151
and rs7234029 were genotyped by PCR and melting curve analysis
usingapairoffluorescenceresonanceenergytransfer(FRET)probes
in a LightCyclerH 480 Instrument (Roche Diagnostics, Mannheim,
Germany) as described in detail in previous studies [28,29,30,
31,32,33]. The PTPN2 SNP rs2542151 was selected from the
GWAS by Parkes et al. [18] and the Wellcome Trust Case Control
Consortium (WTCCC) [20], while the rs7234029 was chosen from
the study of Thompson et al. [24]. All sequences of primers and
FRET probes and primer annealing temperatures used for
genotyping and for sequence analysis are given in tables S1 and S2.
Genotyping of NOD2, IL23R and ATG16L1 variants
Genotyping data of the three main CD-associated NOD2
variants p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066845),
and p.Leu1007fsX1008 (rs2066847) as well as genotyping data
of 10 IL23R SNPs (rs1004819, rs7517847, rs10489629, rs2201841,
rs11465804, rs11209026=p.Arg381Gln, rs1343151, rs10889677,
rs11209032, rs1495965) were available from previous studies
[28],[34,35,36] Nine ATG16L1 variants (rs13412102, rs12471449,
rs6431660, rs1441090, rs2289472, rs2241880 [=p.Thr300Ala],
rs2241879, rs3792106, rs4663396) have also been genotyped in a
previous study [29]. For all genotyping protocols, primer and
probe sequences are available on request.
In silico analysis of transcription factor binding sites
We performed an in silico analysis for potential changes in
transcription factor binding sites caused by the PTPN2 SNPs
rs2542151 and rs7234029 using the online tool TFSEARCH (http://
www.cbrc.jp/research/db/TFSEARCH.html). This tool is based on
theTRANSFAC database whichwas developedatGBF Braunschweig,
Germany [37]. We used a threshold score for binding sites of 75.0
(score=100.0 * (‘weighted sum’ - min)/(max - min); max. score=100).
For both PTPN2 SNPs, major and minor alleles including the flanking
sequences 10 bp upstream and downstream were investigated for
potential changes of binding sites of human transcription factors.
Table 6. Genotype-phenotype associations of the PTPN2 SNP rs7234029 in CD patients.
PTPN2 SNP rs7234029 AA (n=612)A G ( n=253)G G ( n=32)P G ORG [95% CI]
Age at diagnosis (yr) (n=811)
Mean 6 SD 25.80612.36 26.77612.40 25.73612.52 0.197 0.82
Range 1–71 6–78 12–64 [0.61–1.11]
Age at diagnosis (n=811)
,=16years(A1)(n=168) 124 (22.5%) 36 (15.3%) 8 (30.8%) 4.25610
22 0.67 [0.46–0.99] (A1 vs. A2)
17–40 years (A2) (n=546) 357 (64.9%) 173 (73.6%) 16 (61.5%) 0.271 1.30 [0.81–2.09] (A2 vs. A3)
.40 years (A3) (n=97) 69 (12.5%) 26 (11.1%) 2 (7.7%) 0.637 0.87 [0.50–1.53] (A1 vs. A3)
Location (n=764)
Term. ileum (L1) (n=113) 76 (14.8%) 29 (12.6%) 8 (38.1%) 0.978 0.99 [0.65–1.52]
Colon (L2) (n=96) 64 (12.5%) 30 (13.0%) 2 (9.5%) 0.915 1.03 [0.65–1.61]
Ileocolon (L3) (n=545) 364 (71.0%) 170 (73.9%) 11 (52.4%) 0.740 1.06 [0.76–1.48]
Upper GI (L4) (n=10) 9 (1.8%) 1 (0.4%) 0 (0%) 0.157 0.22 [0.03–1.78]
Behaviour (n=686)
Non-stricturing -Non-penetrating (B1) (n=170) 116 (25.4%) 49 (23.0%) 8 (42.1%) 0.682 0.93 [0.64–1.34]
Stricturing (B2) (n=187) 110 (24.1%) 72 (33.8%) 5 (26.3%) 6.62610
23 1.61 [1.14–2.27]
Penetrating (B3) (n=329) 231 (50.5%) 92 (43.2%) 6 (31.6%) 9.06610
22 0.76 [0.56–1.04]
Use of immuno-suppressive agents (n=580) no: 67 (17.2%) 33 (18.8%) 5 (33.3%) 0.433 0.84 [0.54–1.30]
yes: 322 (82.8%) 143 (81.3%) 10 (66.7%)
Surgery because of CD (n=807) no: 260 (47.6%) 111 (47.2%) 16 (61.5%) 0.782 0.96 [0.71–1.29]
yes: 286 (52.4%) 124 (52.8%) 10 (38.5%)
Fistulas (n=821) no: 281 (50.4%) 128 (54.2%) 18 (66.7%) 0.168 0.81 [0.61–1.09]
yes: 277 (49.6%) 108 (45.8%) 9 (33.3%)
Stenosis (n=823) no: 239 (42.8%) 82 (34.3%) 16 (61.5%) 0.111 1.28
yes: 319 (57.2%) 157 (65.7%) 10 (38.5%) [0.95–1.72]
PG: p-value for association comparing carriers of the G-allele to individuals homozygous for A. Association results for age at diagnosis are based on median split.
Uncorrected p-values,0.05 are depicted in bold. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis
tested: n=15, resulting in a significance threshold of p,3.33610
23).
doi:10.1371/journal.pone.0033682.t006
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For data evaluation, we used the SPSS 13.0 software (SPSS Inc.,
Chicago, IL, U.S.A.) and R-2.13.1. (http://cran.r-project.org). Each
genetic marker was tested for Hardy-Weinberg equilibrium in the
control population. Fisher’s exact test was used for comparison
between categorical variables. All tests were two-tailed, considering
p-values,0.05 as significant. Odds ratios were calculated for the
minor allele at each SNP. Bonferroni correction was applied by
calculating the threshold for statistically significant p-values as
follows: p=0.05/n, in which n gives the number of hypotheses
tested. The number of tests applied (n) and the threshold for
statistically significant p-values are given in the legends for all tables
in which Bonferroni correction was applied. Epistasis between
different SNPs was tested using the –epistasis option in PLINK
(http://pngu.mgh.harvard.edu/,purcell/plink/). Haplotype based
association analysis was done with PLINK using the –hap-logistic
option. The two significant SNPs (rs2542151 and rs7234029) of the
single-marker association study were taken into a logistic regression
model for haplotype specific associations. Genotype-phenotype
associations were assessed using logistic regression analysis in R.
Results
PTPN2 gene variants are associated with the
susceptibility to both CD and UC
In all three subgroups (CD, UC, and controls), the allele frequencies
of the PTPN2 SNPs (rs2542151 and rs7234029) were in accordance
with the predicted Hardy-Weinberg equilibrium (Table 2). Our
analysis revealed a significant association of the PTPN2 SNP
rs2542151 with both susceptibility to CD (p=1.95610
25;O R1 . 4 9
[1.34–1.79]) and UC (p=3.87610
22, OR 1.31 [1.02–1.68]).
Moreover, the PTPN2 SNP rs7234029 demonstrated a significant
association with susceptibility to CD (p=1.30610
23; OR 1.35 [1.13–
1.62]) and a trend towards association with UC (p=7.53610
22;O R
1.26 [0.98–1.62]), suggesting PTPN2 as common susceptibility gene
for both CD and UC in the German population.
Haplotype analysis
Next, we analyzed haplotypes formed by the PTPN2 SNPs
rs2542151 and rs7234029 using a logistic regression model for
haplotype-specific associations. The results in table 3 indicate the
strongest association with CD for the TA haplotype with
p=2.37610
25. There were similar results for UC with a p-value
of p=1.52610
22 for the TA haplotype (Table 4).
Genotype-phenotype analysis
Genotype-phenotype analysis (Tables 5, 6, 7, 8) revealed an
association of PTPN2 SNP rs7234029 with a stricturing disease
phenotype (B2) in CD patients (p=6.62610
23; Table 6). In
addition, there were weak associations of the same SNP with an
early onset (A1) of CD (p=4.25610
22; Table 6). Similarly,
PTPN2 SNP rs7234029 modulates disease onset of UC (for A2:
p=3.47610
22; for A3: p=2.51610
22; Table 8). In addition, we
found an association of this SNP with the risk for abscess
Table 7. Genotype-phenotype associations of the PTPN2 SNP rs2542151 in UC patients.
PTPN2 SNP rs2542151 TT (n=226)T G ( n=80)G G ( n=12)P G ORG [95% CI]
Gender (n=318)
Male 125 (55.3%) 36 (45.0%) 5 (41.7%) 8.03610
22 1.54 [0.95–2.51]
Female 101 (44.7%) 44 (55.0%) 7 (58.3%)
Age at diagnosis (yrs) (n=302)
Mean 6 SD 29.45614.60 27.95614.13 25.08615.54 0.253 1.34 [0.81–2.21]
Range 2–81 4–73 9–68
Age at diagnosis (n=302)
,=16 years (A1) (n=59) 41 (19.1%) 16 (21.3%) 2 (16.7%) 0.926 0.97 [0.51–1.83] (A1 vs. A2)
17–40 years (A2) (n=183) 126 (58.6%) 49 (65.3%) 8 (66.7%) 9.95610
22 1.81 [0.89–3.67] (A2 vs. A3)
.40 years (A3) (n=60) 48 (22.3%) 10 (13.3%) 2 (16.7%) 0.189 1.76 [0.76–4.07] (A1 vs. A3)
BMI (kg/m
2) (n=209)
Mean 6 SD 23.9264.74 23.8763.83 23.6764.71 0.995 1.00 [0.55–1.82]
Range 15–54 16–36 15–30
Location (n=200)
Proctitis (E1) (n=24) 15 (12.0%) 7 (10.6%) 2 (22.2%) 0.329 1.55 [0.64–3.70]
Left-sided UC (E2) (n=96) 73 (58.4%) 20 (30.3%) 3 (33.3%) 0.184 0.68 [0.38–1.20]
Extensive UC (E3) (n=80) 37 (29.6%) 39 (59.1%) 4 (44.4%) 0.473 1.22 [0.83–1.80]
Extra-intestinal manifestations (n=191) no: 87 (64.4%) 33 (68.8%) 5 (62.5%) 0.652 0.86 [0.44–1.66]
yes:48 (35.6%) 15 (31.3%) 3 (37.5%)
Use of immuno-suppressive agents no: 50 (26.0%) 14 (20.9%) 2 (22.2%) 0.394 1.32 [0.70–2.50]
(n=268) yes: 142 (74.0%) 53 (79.1%) 7 (77.8%)
Abscesses (n=240) no: 160 (96.4%) 61 (93.8%) 7 (77.8%) 0.151 2.35 [0.73–7.56]
yes: 6 (3.6%) 4 (6.2%) 2 (22.2%)
PG: p-value for association comparing carriers of the G-allele to individuals homozygous for A. Association results for age at diagnosis and BMI are based on median
split. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis tested: n=12, resulting in a significance threshold
of p,4.167610
23).
doi:10.1371/journal.pone.0033682.t007
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22) in UC (Table 8). However, none of
these associations remained significant after Bonferroni correction.
Analysis for epistasis between PTPN2 and the main CD
susceptibility genes NOD2, IL23R and ATG16L1
In addition, we analyzed for potential epistasis between PTPN2
and the three main CD susceptibility genes NOD2, IL23R and
ATG16L1, given recent evidence for a potential functional
interaction between these genes. For example, GRAIL analysis
identified a link between the PTPN2-related gene PTPN22 and
NOD2 [19]. In addition, PTPN2 regulates autophagosome forma-
tion in human intestinal epithelials cells, suggesting a potential link
to ATG16L1 [25]. Epistasis analysis demonstrated weak epistasis
between the ATG16L1 SNP rs2241879 and PTPN2 SNP rs2542151
(p=0.024) in the CD cohort (Table 9) and between ATG16L1 SNP
rs4663396 and PTPN2 SNP rs7234029 (p=4.68610
23) in the UC
cohort (Table 10). However, significance of these associations was
lost after correcting for multiple testing (Bonferroni correction). In
addition, there was no evidence for epistasis between PTPN2 and
CD-associated variants in the NOD2 and IL23R genes.
In silico analysis of PTPN2 SNPs identifies differences in
potential transcription factor binding sites caused by SNP
rs7234029
Finally, we investigated if the two PTPN2 SNPs (including the
surrounding sequences as detailed in the Methods section) result in
changes of transcription factor binding sites. This in silico analysis
demonstrated for SNP rs7234029 differences between major and
minor allele regarding the binding probability of several
transcription factors including GATA-1, GATA-2, GATA-3,
HSF2, NF-kB, C/EBP, E4BP4, SREBP, and HLF. While the
transcription factors GATA-1, GATA-2, GATA-3 and HSF2 were
predicted to bind with very high probability to the sequence
comprising the major A allele, predicted binding to the minor G
allele was substantially lower (Table 11). In contrast, the binding
score for the transcription factors NF- kB, C/EBP, E4BP4,
SREBP, and HLF were higher for the minor G allele. The details
of this analysis are shown in table 11. In contrast, no major
changes regarding transcription factor binding sites were found for
SNP rs2542151 which is located approximately 5.5 kb down-
stream of PTPN2 (data not shown).
Discussion
Our detailed analysis of a large IBD cohort demonstrates that
PTPN2 is a common susceptibility gene for both CD and UC,
adding PTPN2 to the growing list of common susceptibility genes
of CD and UC. So far, 99 IBD susceptibility genes have been
identified (n=71 in CD and n=47 in UC) [19,22]. At least 28
susceptibility loci, including PTPN2, are shared between CD and
UC [19,22]. Our results confirm previous studies in which PTPN2
has been shown to be associated with CD [18,19,20,21]. A very
recent meta-analysis of UC susceptibility genes by Anderson et al.
Table 8. Genotype-phenotype associations of the PTPN2 SNP rs7234029 in UC patients.
PTPN2 SNP rs7234029 AA (n=220) AG (n=83) GG (n=11) PG ORG [95% CI]
Gender (n=314)
Male 119 (54.1%) 42 (50.6%) 5 (45.5%) 0.506 1.18 [0.73–1.91]
Female 101 (45.9%) 41 (49.4%) 6 (54.5%)
Age at diagnosis (yrs) (n=298)
Mean 6 SD 29.95614.90 26.32613.49 30.50612.70 0.401 1.24 [0.75–2.05]
Range 3–81 2–73 14–57
Age at diagnosis (n=298)
,16 years (A1) (n=57) 37 (17.5%) 19 (25.0%) 1 (10.0%) 0.558 1.21 [0.64–2.26] (A1 vs. A2)
17–40 years (A2) (n=181) 125 (59.0%) 49 (64.5%) 7 (70.0%) 3.47610
22 2.24 [1.06–4.73] (A2 vs. A3)
.40 years (A3) (n=60) 50 (23.6%) 8 (10.5%) 2 (20.0%) 2.51610
22 2.70 [1.13–6.45] (A1 vs. A3)
BMI (kg/m
2) (n=207)
Mean 6 SD 23.9764.66 24.1064.26 22.9063.18 0.975 0.99 [0.54–1.82]
Range 15–54 15–36 20–29
Location (n=258)
Proctitis (E1) (n=24) 13 (7.2%) 11 (16.4%) 0 (0%) 7.75610
22 2.15 [0.92–5.05]
Left-sided UC (E2) (n=96) 71 (39.2%) 20 (29.9%) 5 (50.0%) 0.305 0.74 [0.42–1.31]
Extensive UC (E3) (n=138) 97 (53.6%) 36 (53.7%) 5 (50.0%) 0.960 0.99 [0.58–1.68]
Extra-intestinal manifestations (n=188) no: 87 (66.4%) 33 (63.5%) 3 (60.0%) 0.666 1.15 [0.60–2.21]
yes: 44 (33.6%) 19 (36.5%) 2 (40.0%)
Use of immunosuppressive agents (n=266) no: 50 (26.5%) 15 (22.4%) 1 (10.0%) 0.332 1.37 [0.72–2.60]
yes: 139 (73.5%) 52 (77.6%) 9 (90.0%)
Abscesses (n=238) no: 161 (97.0%) 58 (92.1%) 7 (77.8%) 3.94610
22 3.47 [1.06–11.32]
yes: 5 (3.0%) 5 (7.9%) 2 (22.2%)
PG: p-value for association comparing carriers of the G-allele to individuals homozygous for A. Association results for age at diagnosis and BMI are based on median
split. Uncorrected p-values,0.05 are depicted in bold. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis
tested: n=12, resulting in a significance threshold of p,4.167610
23).
doi:10.1371/journal.pone.0033682.t008
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suggesting that PTPN2 is a susceptibility gene for both UC and CD
which is in complete agreement with the results of our study. The
PTPN2 variant rs1893217, which has been shown to be associated
with IBD in several studies [19,22], is in complete linkage
disequilibrium with the PTPN2 SNP rs2542151, which was
investigated in our study. In a smaller analysis from New Zealand,
an association of PTPN2 with CD but not of PTPN22 could be
shown [38]. Studies in an Italian cohort [39] and in a Dutch-
Belgian cohort [40] also reported PTPN2 to be a susceptibility
gene for CD.
In addition, we performed a detailed genotype-phenotype
analysis. Genotype-phenotype analysis revealed an association of
PTPN2 SNP rs7234029 with a stricturing disease phenotype in CD
patients. In addition, we found evidence for weak associations of
rs7234029 and rs2542151 with the age of IBD onset. However,
after Bonferroni correction, most of these associations lost
significance arguing against a strong disease-modifying role for
PTPN2 such as shown for NOD2. Considering that PTPN2
predisposes to both CD and UC, someone may hypothesize that
it would be associated with a predominant colonic disease location;
however, we were unable to show such an association in our
detailed genotype-phenotype analysis.
Moreover, we performed epistasis analysis investigating poten-
tial gene-gene interactions between PTPN2 and the three main
CD susceptibility genes NOD2, IL23R and ATG16L1. A recent
GWAS meta-analysis demonstrated for these three genes the
strongest association of all 71 identified CD risk genes with CD
susceptibility [19]. However, there was no epistasis between
PTPN2 and IL23R, although both genes predispose to autoim-
mune diseases. For example, associations of IL23R could be shown
for CD and UC [3,19], psoriasis [41] and ankylosing spondylitis
[42]. PTPN2 is associated with juvenile idiopathic arthritis [24],
rheumatoid arthritis, celiac disease [19,43], type 1 diabetes [20,44]
and Graves’ disease [44], providing an explanation for the
increased incidence of several of these diseases in IBD patients.
In contrast, epistasis analysis demonstrated evidence for weak
epistasis between the ATG16L1 SNP rs2241879 and PTPN2 SNP
rs2542151 (p=0.024) in the CD cohort and between ATG16L1
SNP rs4663396 and PTPN2 SNP rs7234029 (p=4.68610
23)i n
the UC cohort, which, however, was lost after Bonferroni
correction. Previous studies, including work from our own group
Table 9. Analysis for epistasis between PTPN2 SNPs and gene
markers located in NOD2, IL23R and ATG16L1 in the CD-case
control population.
Epistasis between
PTPN2 SNP
rs2542151
PTPN2 SNP
rs7234029
NOD2 SNPs
rs2066844 (p.Arg702Trp) 0.607 0.498
rs2066845 (p.Gly908Arg 0.219 0.916
rs2066847(p.Leu1007fsX1008) 0.208 0.276
IL23R SNPs
rs1004819 0.556 0.244
rs7517847 0.723 0.916
rs10489629 0.395 0.642
rs2201841 0.303 0.414
rs11465804 0.485 0.887
rs11209026 (p.Arg381Gln) 0.943 0.754
rs1343151 0.277 0.978
rs10889677 0.508 0.417
rs11209032 0.213 0.290
rs1495965 9.86610
22 0.258
ATG16L1 SNPs
rs13412102 0.620 0.358
rs12471449 0.419 0.383
rs6431660 5.73610
22 0.394
rs1441090 0.389 0.437
rs2289472 0.102 0.404
rs2241880 (p.Thr300Ala) 8.07610
22 0.570
rs2241879 2.37610
22 0.382
rs3792106 0.303 0.930
rs4663396 9.76610
22 0.109
Uncorrected p-values,0.05 are depicted in bold. None of the p-values
remained significant after Bonferroni correction for multiple testing (number of
hypothesis tested: n=44, resulting in a significance threshold of
p,1.136610
23).
doi:10.1371/journal.pone.0033682.t009
Table 10. Epistasis between PTPN2 SNPs and gene markers
located in NOD2, IL23R and ATG16L1 in the UC-case control
population.
Epistasis between
PTPN2 SNP
rs2542151
PTPN2 SNP
rs7234029
NOD2 SNPs
rs2066844 (p.Arg702Trp) 0.611 0.219
rs2066845 (p.Gly908Arg 0.385 0.555
rs2066847(p.Leu1007fsX1008) 0.137 0.522
IL23R SNPs
rs1004819 0.869 0.425
rs7517847 0.561 0.972
rs10489629 0.177 0.844
rs2201841 0.711 0.421
rs11465804 0.465 0.265
rs11209026 (p.Arg381Gln) 0.471 0.831
rs1343151 0.525 0.331
rs10889677 0.889 0.303
rs11209032 0.649 0.330
rs1495965 0.847 0.740
ATG16L1 SNPs
rs13412102 0.553 0.749
rs12471449 0.762 8.21610
22
rs6431660 0.298 0.104
rs1441090 0.455 0.544
rs2289472 0.392 0.100
rs2241880 (p.Thr300Ala) 0.536 0.615
rs2241879 0.345 0.423
rs3792106 0.787 0.714
rs4663396 0.217 4.68610
23
Uncorrected p-values,0.05 are depicted in bold. None of the p-values
remained significant after Bonferroni correction for multiple testing (number of
hypothesis tested: n=44, resulting in a significance threshold of
p,1.136610
23).
doi:10.1371/journal.pone.0033682.t010
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play an important role in CD susceptibility and not UC
susceptibility. Given the epistasis between the ATG16L1 SNP
rs4663396 and the PTPN2 SNP rs7234029 in the UC cohort, our
study suggests that autophagy genes may have – in combination
with ‘‘true’’ UC susceptibility genes such as PTPN2 - also a role in
UC susceptibility. However, the rather weak epistasis between
these two genes needs further confirmation in large replication
studies.
The potential epistasis between PTPN2 and ATG16L1 would be
highly interesting, given very recent evidence that PTPN2
regulates autophagosome formation in human intestinal epithelial
cells [25]. Scharl et al. showed that knockdown of PTPN2 causes
impaired autophagosome formation and dysfunctional autophagy
[25]. This resulted in increased levels of intracellular Listeria
monocytogenes and enhanced apoptosis of intestinal epithelial cells in
response to TNF-a and IFN-c [25]. Similar results were found in
primary colonic lamina propria fibroblasts isolated from CD
patients who were carriers of the CD-associated PTPN2 SNP
rs2542151 [25] which was the most strongly CD-associated SNP
in our study. In the study by Scharl et al., presence of the CD-
associated ATG16L1 SNP rs2241880 prevented the TNF-a/IFN-
c-mediated increase in PTPN2 protein expression which resulted
in impaired autophagosome formation [25]. Interestingly, intesti-
nal biopsies from CD patients with either CD-associated ATG16L1
or PTPN2 SNPs showed aberrant expression patterns of LC3B, a
marker for autophagic membranes [25]. Scharl et al. therefore
hypothesized that the combined dysfunction of the CD suscepti-
bility genes PTPN2 and ATG16L1 may contribute to the
pathogenesis of CD [25]. Our results demonstrating epistasis
between CD-associated PTPN2 and ATG16L1 gene variants
support this hypothesis. In addition, it has been shown that
PTPN2 regulates muramyl dipeptide (MDP)-induced autophago-
some formation [45]. These experiments also demonstrated that
the CD-associated PTPN2 variant rs1893217 impairs autophagy
[45]. Given the physical interaction of ATG16L1 and the MDP
receptor NOD2 during autophagy [46], CD-associated PTPN2
variants may increase the CD risk by interfering with ATG16L1-/
NOD2-mediated autophagy. In addition, GRAIL analysis iden-
tified a link between the PTPN2-related gene PTPN22 and NOD2
[19]. However, we were unable to demonstrate epistasis between
PTPN2 and the three main CD-associated NOD2 variants
p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066845), and
p.Leu1007fsX1008 (rs2066847) on a genetic level. Additional
studies suggest that PTPN2 plays an overall protective role in the
intestine, particularly by limiting IFN-c-induced signaling and
consequent barrier defects [47] as well as by modulating TNF-a
responses [48].
To further elucidate the potential functional consequences by
which PTPN2 SNPs modulate IBD susceptibility, we performed an
in silico analysis regarding potential changes in binding sites for
transcription factors. This analysis revealed that the SNP
rs7234029 modulates potentially the binding sites of several
transcription factors including GATA-3, NF-kB, C/EBP, and
E4BP4 which were all shown to be involved in inflammatory
processes. GATA-3 is a major transcription factor involved in
differentiation of Th2 cells [49] which play a fundamental role in
the pathogenesis of UC. NF-kB up-regulates the gene expression
of many proinflammatory cytokines including IL-12 [50].
Together with NF-kB, C/EBP is activated by signaling via pattern
recognition receptors (PRRs) which respond to pathogen-associ-
ated molecular patterns (PAMPs) or host-derived damage-
associated molecular patterns (DAMPs). Both transcription factors
play therefore a pivotal role in inflammatory disorders. E4BP4 is
essential for the development of natural killer (NK) cells and
CD8a+ conventional dendritic cells; it plays also a role in
macrophage activation, polarisation of CD4+ T cell responses
and B cell class switching to IgE [51]. Interestingly, E4BP4 may
also modulate IL-12 expression [52] which plays a key role in the
pathogenesis of CD. The predicted binding of the transcription
factors NF-kB, C/EBP and E4BP4 was stronger to the CD-
associated minor allele of SNP rs7234029 than to the protective
major allele, suggesting that the increased CD risk may be partially
modulated via the stronger activation of these proinflammatory
transcription factors.
In summary, we confirm PTPN2 as common susceptibility gene
for CD and UC. Genotype-phenotype analysis could not identify a
clear phenotype associated with these variants. A potential
association of PTPN2 SNP rs7234029 with a stricturing disease
phenotype in CD patients (p=6.62610
23) needs further confir-
mation in larger cohorts or meta-analyses which are currently
organized by the subphenotyping committee of the International
Table 11. Potential transcription factor binding sites in the genomic region harboring the PTPN2 SNP rs7234029.
Transcription factor
Binding score
major allele (A)
Binding score
minor allele (G) Consensus sequence
Position
relative to SNP
GATA-X 95.2 80.1 NGATAAGNMNN 22t o+8
GATA-1 94.8 80.2 NNCWGATARNNNN 25t o+7
GATA-2 85.8 65.8 NNNGATRNNN 24t o+5
GATA-3 83.4 64.1 NNGATARNG 23t o+5
HSF2 75.0 62.2 NGAANNWTCK 23t o+6
NF-kB 68.5 79.4 GGGAMTTYCC 21t o+8
C/EBP 69.5 78.5 NGWNTKNKGYAAKNSAYA 28t o+9
E4BP4 65.7 76.0 NRTTAYGTAAYN 26t o+5
SREBP 67.2 75.0 NATCACGTGAY 26t o+4
HLF 66.9 75.0 RTTACTYAAT 25t o+4
The potential transcription factor binding sites were analyzed in silico with the program TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html.). Only binding sites
with binding score differing more that 5 points between the two alleles are presented. Scores differing more than 10 points are depicted in bold. The binding score
threshold for each allele was set to 75.0.
Nucleotide codes: K=G or T, M=A or C, R=A or G, S=C or G, W=A or T, N=A, G, C or T.
doi:10.1371/journal.pone.0033682.t011
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increased CD risk mediated by rs7234029 may be related to a
stronger activation of proinflammatory transcription factors such
as NF-kB, C/EBP and E4BP4. This study revealed a potential
interaction between PTPN2 and ATG16L1 regarding susceptibility
of CD and UC. However, given the rather weak interaction, this
has to be further investigated. Interestingly, this finding supports
the results of a very recent functional study demonstrating a major
role for PTPN2 in the autophagosome formation in human
intestinal epithelial cells [25]. This suggests that different IBD-
related pathways may converge in common functional ‘‘end-
points’’ such as autophagy resulting in increased IBD susceptibility
in affected patients.
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